Relevance: At the moment, the study relevance is determined by extremely insufficient coverage of this issue, which in turn directly affects managing patients with this pathology.

Study objectives: To identify predictors of adverse outcomes; to construct a prognostic model for patients with acute limb ischemia and severe acute respiratory syndrome-related coronavirus-2 (hereinafter – SARS-Cov-2). 

Material and methods: Study design: single-center, retrospective study. We retrospectively analyzed 47 patients with acute limb ischemia (ALI) on confirmed SARS-Cov-2 for the period from September 2020 to April 2022. In this study, we analyzed the mean age of patients, laboratory tests results, comorbidities, ischemia grade, imaging data, choice of treatment strategy, and in-hospital mortality. Statistical analysis revealed a correlation between clinical outcomes in patients with ALI and SARS-Cov-2 severity.

Results: SARS-CoV-2 was confirmed in 100% of patients. The distribution of ALI grades (according to I.I. Zatevakhin's clasification) was as follows: 1 – 8.5% (n = 4); 2A - 44% (n = 21); 2B – 39% (n = 18); 3A – 8.5% (n = 4); 78.5% of patients received anticoagulants. Patients were grouped by intervention type: selective thrombolysis – 9%, surgical thrombectomy – 10%, endovascular interventions – 63%, hybrid interventions – 18%. Clinical outcomes (all-cause mortality, major cardiovascular events, repeat revascularization) were retrospectively evaluated. Using regression analysis, we found a correlation between the end-point and the severity of the underlying disease, assessed predictors of adverse outcomes, and constructed a prognostic model. In-hospital mortality was 65.3%.

Conclusion: Our prognostic model allowed to find a correlation between clinical and laboratory data and the end-point.